As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted Prof. Ian Pavord for a webinar on “Biomarkers of Inhaled Corticosteroid Respond in COPD” on 20 June 2016.
Corticosteroid treatment is effective at reducing exacerbation rates in people with COPD. The benefit of treatment is balanced by an increased risk of pneumonias and steroid-associated side effects. Biomarkers have been proposed to identify the patients most likely to respond to steroid treatment.
Biomarkers can provide information about the mechanisms underlying disease in individual patients. Eosinophil numbers are increased in a subset of COPD patients. Increased sputum eosinophil numbers are associated with a better response to steroid treatment.
Blood eosinophil counts are more readily accessible than sputum assessment. Blood eosinophil counts are a useful biomarker of COPD exacerbations. Increased blood eosinophil counts also predict response steroid treatment.
A “treatable traits” approach to treating airways disease is proposed. Treatment should be targeted to the disease mechanisms identified in each patient.
Prof. Ian Pavord is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals.
He has published 260 scientific papers, including three of the 20 most cited papers in the field in the last 10 years. He has an H-index of 65. His main contribution has been to develop new methods to assess and treat airway inflammation and airway diseases.
He has been joint Chief Medical Advisor to Asthma UK since May 2008 and joint Editor of Thorax since 2010.
Prof. Pavord’s travel was supported by Menarini.